Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
51 hedge funds and large institutions have $167M invested in Agile Therapeutics in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
2% more funds holding
Funds holding: 50 → 51 (+1)
9% less capital invested
Capital invested by funds: $184M → $167M (-$16.8M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$4.15M |
| 2 |
PA
Perceptive Advisors
New York
|
+$3.61M |
| 3 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$1.38M |
| 4 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
+$400K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$385K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$6.49M |
| 2 |
SAM
Senzar Asset Management
New York
|
-$2.75M |
| 3 |
AC
Aisling Capital
New York
|
-$2.2M |
| 4 |
RA
Royce & Associates
New York
|
-$614K |
| 5 |
JGC
J. Goldman & Co
New York
|
-$514K |
AGRX Hedge Fund Activity: Q3 2016 in Review
51 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q3 2016, worth a combined $167M — down 9.1% from $184M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new AGRX positions and 5 closed out — a net gain of 1 holder — while 11 added to existing stakes and 10 trimmed.
The largest buyer was Invesco, adding an estimated $4.15M. The largest seller was RA Capital Management, exiting entirely with an estimated $6.49M sold.
- 51 institutional investors held Agile Therapeutics (AGRX) as of Q3 2016, up from 50 in Q2 2016.
- Funds reported $167M of Agile Therapeutics stock for Q3 2016, down 9.1% quarter-over-quarter.
- 6 funds opened new Agile Therapeutics positions in Q3 2016 and 5 closed out, a net change of +1 holder.
- The largest Agile Therapeutics buyer in Q3 2016 was Invesco, an estimated $4.15M added.
- The largest Agile Therapeutics seller in Q3 2016 was RA Capital Management, an estimated $6.49M sold.
Based on aggregated 13F filings for Q3 2016.